Adicet Bio Inc. (ACET)
Adicet Bio Inc. (ACET) Stock Price, Analysis & Data
| Bid | 5.93 |
| Market Cap | 77.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -98.97M |
| Beta | 1.59 |
| EPS (ttm) | -10.42 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.74 |
| P/B (ttm) | 0.74 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 11, 2026 |
| Ask | 10.5 |
| Volume | 20,957 |
| Avg. Volume (20D) | 96,687 |
| Open | 8.32 |
| Previous Close | 8.23 |
| Day's Range | 8.18 - 8.35 |
| 52-Week Range | 6.01 - 17.44 |
| Analyst | Strong Buy |
| Price Target | 22.5 (172.40%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candida...
Financial Performance
In 2025, Adicet Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -116.8M, a decrease of -0.27%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for ACET stock is "Strong Buy". The 12-month stock price forecast is 22.5, which is upside of 172.4% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
